MM-111
Asset
Bispecific antibody targeting ErbB2 and ErbB3 receptors to inhibit downstream oncogenic signaling.
- Stage
- Phase 1
- Modality
- Antibody
- Target
- ERBB2
- 1
- Indication
- 2,008
- Trials
- 1
- Developer
Indications
1Her 2 gene amplification
Phase 1, Completed, NCT01304784, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials2,008
- Evidence for its targets3
- Competitors10
Every asset’s record: target, stage, trials and the evidence behind it.